ERCC1-tailored chemotherapy in lung cancer: The first prospective randomized trial

Journal of Clinical Oncology

Volumn 25, Issue 19, 2007, Pages 2648-2649

  Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; GENOMIC DNA; MESSENGER RNA; OXALIPLATIN; PLATINUM; ANTINEOPLASTIC AGENT; DNA; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA REPAIR; DRUG INHIBITION; DRUG MECHANISM; EDITORIAL; EXCISION REPAIR; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SMOKING; STOMACH CANCER; TREATMENT OUTCOME; BIOSYNTHESIS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; METHODOLOGY; NOTE; ONCOLOGY; PROGNOSIS; PROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DNA; DNA-BINDING PROTEINS; ENDONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 34447534435     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.3167     Document Type: Editorial

References (12)

1. Ruckdeschel JC, Schwartz AG, Bepler G: Cancer of the lung: NSCLC and SCLC, in Clinical Oncology. New York, NY, Elsevier, 2004, pp 1649-1743
2. Kwon HC, Roh MS, Oh SY, et al: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18:504-509, 2007
3. Bellmunt J, Paz-Ares L, Cuello M, et al: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18:522-528, 2007
4. Bepler G, Kusmartseva I, Sharma S, et al: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24:47314737, 2006
5. Dabholkar M, Bostick-Bruton F, Weber C, et al: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512-1517, 1992
6. Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clinical Cancer Res 8:2286-2291, 2002
7. Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16:309-316, 1998
8. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006
9. Zheng Z, Chen T, Li X, et al: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800-808, 2007
10. Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. J Clin Oncol 25:2747-2754, 2007
11. Aschele C, Debernardis D, Tunesi G, et al: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6:4797-4802, 2000
12. Italiano A, Vandenbos FB, Otto J, et al: Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: Implications for treatment with EGFR-inhibitors. Ann Oncol 17:981-985, 2006